Back

The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction

30 August 2026 (12:12 - 12:24)
Organised by: Logo
Congress Presentation Part of: Optimising pharmacotherapy in heart failure Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rafael Rascon Sabido

Mexican Institute of Social Security (IMSS), Veracruz (Mexico)

4 More presentations in this session

Presentation thumbnail
Evaluation of machine learning framework for personalized prediction of benefit from beta-blockers in myocardial infarction with preserved or mildly reduced ejection fraction
Doctor Y. Chen (Beijing, CN)
Abstract
Presentation thumbnail
Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY
Doctor J. Ostrominski (Boston, US)
Abstract
Presentation thumbnail
Finerenone-related initial declines in eGFR and urinary biomarkers of tubular injury: mechanistic insights from the FIVE-STAR trial
Doctor M. Vaduganathan (Boston, US)
Abstract
Presentation thumbnail
Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF
Doctor R. Ono (Glasgow, GB)
Abstract

Access the full session

Session thumbnail
Optimising pharmacotherapy in heart failure

The Event

Event poster

ESC Congress 2026

30 August 2026 12:12 CET
You may be interested in
thumbnail
Congress Presentation
Boosting secondary prevention: efficacy and adherence of inclisiran in post-acute coronary syndrome very high-risk patients
3 April 2025
thumbnail
Congress Presentation
Sacubitril-valsartan and its effect on echocardiographic parameters
29 June 2021
thumbnail
Congress Presentation
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
30 August 2020
thumbnail
Congress Presentation
Efficacy of half-dose intermittent levosimendan in day hospital for reduce mortality and hospitalization in patients with heart failure and reduced ejection fraction
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources